100 Migraine Drugs, A to Z: rizatriptan

July 21, 2020

Rizatriptan (Maxalt, Maxalt MLT) is one of the seven triptans approved in the US. Along with zolmitriptan, it is one of the two triptans available in an orally disintegrating form – it melts in your mouth and does not require water to take it. This is important for those migraine sufferers who are so nauseous that they cannot drink even a small amount of fluid without throwing it up. It also means that you can take it when water is not immediately available. This is important since the earlier you take an abortive drug the better the results.

Another unique feature of rizatriptan is that the FDA-approved dose is up to three 10-mg tablets a day (it is also available in 5-mg tablets), while all other triptans have a limit of 2 a day. This does not mean that there is any significant difference in how different short-acting triptans are processed in your body or that taking sumatriptan three times in one day is dangerous. Unfortunately, many doctors blindly follow the rules and sternly warn patients not to exceed the FDA-recommended dose. The 5 most effective triptans (this excludes naratriptan and especially frovatriptan) have a half-life of 2-3 hours, which means that half of a single dose is gone from your body in 2-3 hours and after 6-8 hours, almost all of it is washed out. Naratriptan has a half-life of 6 hours and frovatriptan, 26 hours. Even if you were to take narartriptan three times a day it would not endanger your life, unless you have coronary artery disease or another contraindication to triptans in general.

These contraindications include uncontrolled hypertension, history of a stroke or a heart attack, and multiple risk factors for coronary artery disease. You may still be able to take triptans if you have some risk factors, but you would need to have your coronary arteries checked with coronary calcium scoring, stress test, or an angiogram.

Written by
Alexander Mauskop, MD
Continue reading
March 26, 2026
Alternative Therapies
Lidocaine-Based Treatments Offer Another Option for Severe Migraines
This post explains how lidocaine, beyond its traditional use as a local anesthetic, can be given by IV or directly into the middle meningeal artery to help break severe, treatment-resistant migraines, with early studies showing promising relief and generally mild, manageable side effects.
Read article
February 16, 2026
News
Potential big news for the 40 million Americans with migraine.
It is long overue to make triptans available without a prescription, like in the rest of the world.
Read article